Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alfuzosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.98 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.98 |
| ▸ | GLA | P06280 | 6/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.98 |
| ▸ | HPGD | P15428 | 6/20 | 0.98 |
| ▸ | GAA | P10253 | 5/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.98 |
| ▸ | ACHE | P22303 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfuzosin SCHEMBL4744369 | 1.00 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL30690015 | 1.00 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL2851348 | 1.00 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL29492949 | 1.00 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL8115183 | 0.99 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL1690751 | 0.99 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL1690827 | 0.99 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL8108037 | 0.99 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL34477 | 0.99 | KDM4E (1.00) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL415972 | 0.99 | KDM4E (1.00) | KDM4EGLAALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| CN-118169271-A | Method for detecting alpha-adrenergic receptor blocker, SSRI and 5-ARIs and application thereof | 巴中市产品质量检验检测中心 | 2024-06-11 | — | — | CN | claimed |
| CN-118063448-A | Preparation method of alfuzosin hydrochloride | 山东新时代药业有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-113801069-B | Alfuzosin hydrochloride intermediate compound | 鲁南制药集团股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-114209668-B | Alfuzosin hydrochloride sustained release preparation and preparation method thereof | 山东新时代药业有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115337285-A | Alfuzosin hydrochloride sustained-release pellet capsule and preparation method thereof | 山东新时代药业有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-114209668-A | Alfuzosin hydrochloride sustained release preparation and preparation method thereof | 山东新时代药业有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-113801069-A | Alfuzosin hydrochloride intermediate compound | 鲁南制药集团股份有限公司 | 2021-12-17 | — | — | CN | claimed |
| US-20200095627-A1 | MOLECULAR SENSORS AND USES THEREOF | NEW YORK UNIVERSITY | 2020-03-26 | — | — | US | claimed |
| US-10154856-B2 | Therapeutic substance transfer catheter and method | SILLENDER MARK (AU) | 2018-12-18 | — | — | US | claimed |
| US-20040115259-A1 | Method for producing a floating tablet containing an active principle and the tablet obtained | BROCADE COMMUNICATIONS SYSTEMS, INC. | 2004-06-17 | — | — | US | claimed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-0673650-B1 | Pharmaceutical sustained-release dosage forms containing alfuzosine hydrochloride | SANOFI SYNTHELABO (FR) | 2001-08-01 | — | — | EP | claimed |
| EP-0938318-B1 | TABLET WITH CONTROLLED RELEASE OF ALFUZOSINE CHLORYDRATE | SANOFI SYNTHELABO (FR) | 2001-05-02 | — | — | EP | claimed |
| US-6149940-A | BIOAVAILABILITY; ON CONTACT WITH GASTRIC JUICES, AFTER RAPID AND CONSIDERABLE SWELLING OF LAYERS INCREASES CONSIDERABLY IN VOLUME, THUS, THE PHARMACEUTICAL PREPARATION REMAINS IN THE STOMACH FOR LONGER; DRUG DELIVERY, TIME RELEASE AGENTS | SYNTHELABO (FR) | 2000-11-21 | — | — | US | claimed |
| US-5589190-A | HYPOTENSIVE AGENTS AND ANTITUMOR AGENTS | SYNTHELABO (FR) | 1996-12-31 | — | — | US | claimed |
| US-5545738-A | USEFUL FOR PRODUCTION OF ANTIHYPERTENSIVE AGENTS AND DYSUREA CURING AGENTS | SYNTHELABO (FR) | 1996-08-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | ADRA1D 651/4885ADRA1A 434/4885ADRA1B 364/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | ADRA1D 593/4885ADRA1A 687/4885ADRA1B 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.